JP Morgan Healthcare Conference
A New Era of Pfizer R&D Productivity

Mikael Dolsten, M.D., Ph.D.
President, Worldwide R&D
January 8, 2018
This presentation includes forward-looking statements about, among other things, our in-line products and product candidates, including anticipated regulatory submissions, data read-outs, approvals, performance, timing of exclusivity, potential benefits of Pfizer’s products and product candidates, and anticipated future operating and financial performance that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Additional information regarding these factors can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2016 and in our subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in our subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com. The forward-looking statements in this presentation speak only as of the original date of this presentation and we undertake no obligation to update or revise any of these statements.
Step Change in Pfizer R&D Productivity
Actual and potential blockbuster approvals (as of January 2018)

Up to 15 in 5 Years*

1. IO-IO: Mono/Combo
2. IO-Targeted / IO-Chemo
3. Targeted Cancer Agents (Collective) (talazoparib, lorlatinib, dacomitinib, glasdegib)
4. Ibrance® Intermediate/High Risk eBC
5. Xtandi® non meta. PROSPER/EMBARK
6. JAK1 Atopic Dermatitis
7. JAK ‘X’ Alopecia/Vitiligo
8. Xeljanz LCM
9. Clostridium Difficile
10. Staphylococcus Aureus
11. Pneumococcal Nextgen
12. domagrozumab Duchenne
13. rivipansel Sickle Cell
14. tafamidis Cardiomyopathy
15. tanezumab Pain

*Subject to attrition

Note: Examples reflect when cumulative Peak Year Sales are anticipated to exceed $1B.
Potential 2018 Milestones

**LATE STAGE**

- Xtandi®
  - nmCRPC PROSPER Submission (US/EU)
- talazoparib
  - EMBRACA Submission (US/EU)
- Bavencio®
  - NSCLC 2L Phase 3 Data
- Vyndaqel®
  - Cardiomyopathy Phase 3 Data
- Xeljanz®
  - Ulcerative Colitis Action Date (US/EU)
- Iorlatinib
  - NSCLC 2L Action Date (US)
- rivipansel
  - Sickle Cell Phase 3 Data
- tanezumab
  - OA/CLBP Pain Phase 3 Data

**1H 2018**

- Ibrance® Combo
  - PDAC Phase 1 Data
- TFPI mAb
  - Hemophilia Phase 1b/2 Data
- JAK3
  - Rheumatoid Arthritis Phase 1 Data
- Anti IL-33
  - Atopic Derm Phase 1 Data

**EARLY STAGE**

- Selective JAK’s
  - Alopecia, Psoriasis Phase 2 Data
- Bavencio® Triplet
  - + 4-1BB + OX-40 Phase 1 Data
- PNG 20, GBS, VBIR1 Vaccines Phase 1 & 2 Data
- ACC, FK, GLP1 NASH Phase 1 & 2 Data
Discussion